Latest Orion Pharma News & Updates

See the latest news and media coverage for Orion. We track all announcements, press releases, and industry mentions in real time, all in one place.

Orion Pharma (Orion)

Finnish pharmaceutical company

orionpharma.com

Headquarters: Espoo, Finland
Company type: Public company
Number of employees: 3,000–5,000

Last updated Today

Latest news about Orion Pharma (Orion)

In short: Orion reported strong 2025 financial growth, advanced its oncology pipeline with ODM-212 trials, and achieved carbon-neutral production in Turku.

Company announcements

June 10 Orion

Orion commits to 70% emissions reduction by 2030.

The target covers Scopes 1&2 and relies on energy efficiency, electrification, and carbon-free sources.

June 10 Orion

Orion discloses BlackRock's stake fell below 5%

BlackRock Inc. and its funds now hold 4.92% of shares and 0.10% via financial instruments, total 5.03%.

June 5 Orion

Orion discloses BlackRock's stake increase above 5%

BlackRock Inc. and its funds now hold 5.06% of shares and voting rights as of June 4, 2026.

May 15 Orion

Orion converted 105,950 A shares into B shares

The conversion was entered into the Trade Register on 15 May 2026, altering the share structure.

Media coverage

June 16 GlobeNewswire

Orion Oyj: Announcement in accordance with Chapter 9, Section 10 of the Securities Markets Act (BlackRock, Inc.)

Orion Pharma is a Finnish pharmaceutical company – a builder of well-being that operates globally. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Our operations combine a solid...

June 3 Yahoo Finance

Orion Oyj Hippo Pathway Data Adds New Dimension To Oncology Story

Orion Oyj presented first-in-human Phase 1 data for its pan-TEAD inhibitor ODM-212 at the 2026 ASCO Annual Meeting. The trial targets advanced solid tumours, including...

June 1 MSN

Orion Pharma reports Phase I data from TEADES trial for solid tumours

The results showed ODM-212 was well tolerated, with no dose-limiting toxicities and no maximum tolerated dose reached.

May 30 Kauppalehti

Orion Pharma announced the first results from the Phase 1/2 TEADES study with the ODM-212 molecule (TEAD inhibitor) in patients with solid tumors and advanced cancer.

The results were presented at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting and show that the ODM-212 molecule was well tolerated. Protein excretion in urine (proteinuria...

Never miss news about Orion

Track Orion and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Orion competitors & trending companies

Browse news for competitors to Orion and other trending companies.